topic
Good news about Pharmaceuticals
Positive stories about Pharmaceuticals, gathered from the newsrooms Rally reads. Every headline links back to the publisher who reported it.
9 stories.
Bristol Results Show Promise in Rare Cancer, Lung Disease
Bristol Myers Squibb Co.’s experimental drugs for treating a rare endocrine cancer and a deadly form of lung disease showed promise in late-stage studies, a potential boon for the pharmaceutical company’s new product pipeline.
Bloomberg
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Agenus reports that its combination therapy for recurrent ovarian cancer maintained a 48% estimated three-year survival rate, offering hope for a heavily pretreated population. Nearly three-quarters of patients had platinum-resistant or refractory cancer, making the results particularly meaningful. The durable benefit extends evidence of long-term effectiveness in a difficult-to-treat group.
Financial Post
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Drugmakers are developing amylin-based treatments to complement or expand on existing obesity and diabetes drugs, offering new options for those who don’t respond well to current GLP-1 therapies. This could help millions of people achieve better health outcomes.
CNBC
Why rare-disease drugs could become India’s next pharma frontier
India is leveraging its expertise in affordable drug production to tackle rare-disease treatments, aiming to make them more accessible. By improving regulations, offering financial incentives, and securing government support, the country could become a global leader in this field. This shift could bring life-changing medicines to patients who need them most.
The Hindu
EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences
Galderma will share new research on skin diseases, longevity, and patient experiences at the 2026 EADV Congress, including long-term data on its Nemluvio treatment. The findings aim to improve understanding and care for dermatology patients. This progress highlights ongoing innovation in skin health.
Financial Post
Study attempts to find out how India made expensive diabetes medicines affordable
India’s policies allow generic drug production, making diabetes medicines far more affordable. The approach, backed by legislation, helps millions access treatment while supporting the country’s role as a global pharmaceutical exporter. This model could offer lessons for other nations facing high drug costs.
The Hindu
Teva Announces New Olanzapine LAI (TEV-‘749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Teva’s new long-acting injectable for schizophrenia, TEV-‘749, showed high stabilization rates and long-term efficacy in a Phase 3 trial. More than half of participants stabilized, and over a fifth achieved remission after six months. This could offer a more convenient, effective treatment option for adults with the condition.
Financial Post
Dr. Reddy's, Takeda Pharma ink pact to distribute India's first dengue vaccine QDENGA
A new partnership will bring India’s first dengue vaccine, QDENGA, to more people. Pending regulatory approval, it could be available by early 2027, offering hope for better protection against the disease. This collaboration aims to expand access to a much-needed medical breakthrough.
The Hindu
Medisca Launches Global Peptide Division
Medisca has launched a new global division focused on expanding access to API-grade peptides, enhancing the pharmaceutical and personalized medicine landscape. This initiative reflects a strong commitment to building the necessary capabilities and infrastructure to support high-quality peptide production within regulatory frameworks. The development is a positive step towards improving the availability of personalized treatments.
Financial Post
